What are the main indications for eltrombopag treatment?

Eltrombopag (Eltrombopag) is an oral thrombopoietin receptor agonist, which mainly stimulates the proliferation and differentiation of megakaryocytes in the bone marrow, thereby promoting platelet production. The drug was first developed by Novartis and is widely used to treat a variety of thrombocytopenia-related diseases, especially for patients who are ineffective or intolerant to traditional treatments.

Eltrombopag is widely used to treat chronic immune thrombocytopenic purpura (ITP). For adult and pediatric patients with chronic ITP who still have low platelet counts and are at risk of bleeding after glucocorticoids, immunoglobulins, or splenectomy, eltrombopag can significantly increase platelet counts, reduce the risk of bleeding, and improve quality of life. These patients rely on blood transfusions or hormone therapy for many years. The emergence of eltrombopag provides a long-term, safe, non-invasive treatment alternative.

Eltrombopag is also used to treat secondary thrombocytopenia due to hepatitis C. Patients with chronic hepatitis C who are receiving antiviral treatment (such as interferon treatment) often need to interrupt treatment if their platelet count is too low. Eltrombopag can stabilize platelet counts in such patients, allow antiviral treatment to continue, increase viral clearance, improve treatment compliance, and avoid disease progression due to drug discontinuation.

Eltrombopag is also approved for the treatment of severe aplastic anemia (SAA). When patients fail to respond to immunosuppressive treatment, eltrombopag can be used as one of the treatment options to help stimulate multi-lineage hematopoiesis and improve platelet, red blood cell and white blood cell levels. Studies have shown that in some patients with refractory aplastic anemia, eltrombopag can not only increase platelets, but also promote the recovery of three lineage blood cells, which has important clinical significance.

In short, eltrombopag is a multi-indication platelet production promoter, mainly suitable for chronic ITP, hepatitis C-related thrombocytopenia, severe aplastic anemia and other diseases. By activating the TPO receptor, it can effectively increase platelet levels, reduce the risk of bleeding, and significantly improve the patient's quality of life. It is an important choice for the current clinical treatment of various blood system diseases.

Reference materials:https://go.drugbank.com/drugs/DB06210